See more : ISE Chemicals Corporation (4107.T) Income Statement Analysis – Financial Results
Complete financial analysis of Rezolute, Inc. (RZLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rezolute, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tongyu Communication Inc. (002792.SZ) Income Statement Analysis – Financial Results
- Enterprise 4.0 Technology Acquisition Corp. (ENTF) Income Statement Analysis – Financial Results
- Profarma Distribuidora de Produtos Farmacêuticos S.A. (PFRM3.SA) Income Statement Analysis – Financial Results
- SRJ Technologies Group Plc (SRJ.AX) Income Statement Analysis – Financial Results
- Al Sagr Cooperative Insurance Company (8180.SR) Income Statement Analysis – Financial Results
Rezolute, Inc. (RZLT)
About Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 12.57M | 8.27M | 5.85M | 2.40M | 4.56M | 4.84K |
| Gross Profit | -36.00K | -382.00K | -256.00K | -303.00K | -18.00K | -48.00K | -1.07M | -12.57M | -8.27M | -5.85M | -2.40M | -4.56M | -4.84K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.74M | 43.81M | 32.49M | 14.99M | 14.45M | 19.08M | 17.28M | 12.09M | 9.45M | 4.70M | 34.32K | 3.49K | 0.00 |
| General & Administrative | 196.00K | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67M |
| Selling & Marketing | 14.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -42.63M |
| SG&A | 14.64M | 12.18M | 9.36M | 7.91M | 6.07M | 6.82M | 9.10M | 8.23M | 5.50M | 6.00M | 5.13M | 6.10M | 42.67K |
| Other Expenses | 0.00 | 0.00 | -231.00K | -515.00K | 0.00 | 321.00K | 136.13K | 37.14K | 5.33M | 3.51M | 11.30K | 295.00 | 6.62M |
| Operating Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 42.67K |
| Cost & Expenses | 70.42M | 55.99M | 41.61M | 22.38M | 20.52M | 25.90M | 26.38M | 20.32M | 14.95M | 10.70M | 5.18M | 6.11M | 47.51K |
| Interest Income | 0.00 | 4.21M | 80.00K | 63.00K | 188.00K | 61.00K | 1.00K | 0.00 | 965.00 | 4.97K | 12.18K | 106.04K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.81M | 375.00K | 0.00 | 4.96M | 689.19K | 1.60K | 5.04K | 6.73K | 4.23M | 568.86K | 0.00 |
| Depreciation & Amortization | 36.00K | 382.00K | 256.00K | 303.00K | 18.00K | 48.00K | 1.07M | 1.11M | 751.25K | 134.13K | 11.30K | 295.00 | 221.00 |
| EBITDA | -68.42M | -51.41M | -41.83M | -22.88M | -20.32M | -25.44M | -28.11M | -19.16M | -14.18M | -11.22M | -5.49M | -6.16M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -70.42M | -55.99M | -41.84M | -22.89M | -20.52M | -25.94M | -28.73M | -20.32M | -14.95M | -10.70M | -5.18M | -6.11M | -45.73K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 4.20M | 783.00K | 1.99M | 188.00K | -4.50M | -1.13M | 46.92K | 15.75K | -664.48K | -4.55M | -620.58K | -1.78K |
| Income Before Tax | -68.46M | -51.79M | -41.06M | -20.90M | -20.33M | -30.45M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -47.51K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -137.90K | -2.28M | 375.00K | -297.00 | -29.00K | 2.93M | -11.37K | -19.82K | 662.72K | 336.49K | 157.76K | 3.56K |
| Net Income | -68.46M | -51.79M | -38.78M | -21.28M | -20.33M | -30.42M | -29.86M | -20.28M | -14.94M | -11.36M | -9.73M | -6.73M | -49.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -1.01 | -2.13 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| EPS Diluted | -1.33 | -1.01 | -1.99 | -2.77 | -3.54 | -17.11 | -26.83 | -24.55 | -30.14 | -27.12 | -51.84 | -54.21 | -0.64 |
| Weighted Avg Shares Out | 51.47M | 51.19M | 18.20M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
| Weighted Avg Shares Out (Dil) | 51.47M | 51.19M | 19.49M | 7.67M | 5.75M | 1.78M | 1.11M | 825.93K | 495.46K | 419.00K | 187.69K | 124.09K | 77.35K |
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has...
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
The FDA bestows an Orphan Drug status to Rezolute's ersodetug for treating hypoglycemia due to tumor hyperinsulinism. Shares rise.
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market
Rezolute, Inc. expects to report top-line results from the phase 3 sunRIZE study using ersodetug + placebo to treat patients with Congenital Hyperinsulinism in the 2nd half of 2025. The global Congenital Hyperinsulinism treatment market is estimated to be worth...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.
RZLT Stock Up as FDA Lifts Clinical Holds on Rare Disease Study
The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.
FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment
Monday, the FDA removed partial clinical holds on Rezolute, Inc.'s RZLT RZ358 (ersodetug), a potential treatment for hypoglycemia (low blood sugar) caused by congenital hyperinsulinism (HI).
US FDA lifts partial clinical hold on Rezolute's blood sugar treatment
Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company's Expanded Access Program REDWOOD CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or...
Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds
Source: https://incomestatements.info
Category: Stock Reports